COMPANY RESEARCHPepiX™ connects AI, automated synthesis, and experimental screening. The website identifies oral cyclic peptides as a priority; food-peptide GRAS status is not pharmaceutical evidence.
Convertible bond principal; neither IPO net proceeds nor the 2025 placement amount.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY IFRS / consolidated | 802,623,000 | 123,747,000 Net income attributable to owners of the parent | -165,411,000 | Original ↗ |
| 2026H1 2026-06-30 | CNY IFRS / consolidated | 393,627,000 | -251,901,000 Net income attributable to owners of the parent | -399,238,000 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
PepiX™ connects AI, automated synthesis, and experimental screening. The website identifies oral cyclic peptides as a priority; food-peptide GRAS status is not pharmaceutical evidence.
The solid-state platform combines prediction and experiments and offers a dedicated crystal structure determination service.
The structure determination page lists small-molecule drugs, salts, cocrystals, mixtures, and structural isomers and discloses a Glacios 200 kV platform.
XtalGazer uses prediction and experiments for solid-form selection. Experimental and computational evidence must be distinguished for each project.
Original 2025 and 2026 interim earnings announcements disclose drug-discovery solutions revenue and group results.
Listed entity HKEX 2228; financials are consolidated group figures.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| PepiX™ oral cyclic peptide research | Not disclosed · Not disclosed | 未披露 | Quantitative human results not confirmed in this review |
| Solid-state R&D capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
| MicroED / 3D ED service capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
| AI drug discovery and laboratory services | Client-specific projects · Client-specific projects | Services / platform | Service capability does not represent clinical evidence for a proprietary candidate |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
This article explores how Microcrystal Electron Diffraction (MicroED) is set to revolutionize drug polymorph research workflows. Drawing upon recent news, official websites, and LinkedIn updates from Crystal Pharmatech and Eldico, it clearly distinguishes between verified facts, industry viewpoints, and information pending verification.
Direct Electron lists a REyes webinar for November 10, 2026, at noon Eastern Time. It will discuss diffraction-guided screening, automated acquisition and structure solution, including integration with SerialEM.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
